Ionis Pharmaceuticals (IONS)
(Delayed Data from NSDQ)
$41.59 USD
-0.25 (-0.60%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $41.60 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Company Summary
Based in Carlsbad, CA, Ionis Pharmaceuticals discovers/develops RNA-targeted therapeutics using its proprietary antisense oligonucleotide technology. The company leverages this technology to generate a broad pipeline of medicines, targeting neurological, cardiovascular and specialty rare diseases, for itself as well as its partners.
Ionis has phase III studies ongoing for nine medicines (internal as well as partnered) across 11 indications. These include tofersen for amyotrophic lateral sclerosis (ALS) with superoxide dismutase 1 (SOD1) mutations; pelacarsen for cardiovascular disease due to elevated Lp(a) levels; olezarsen for familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG); eplontersen for ...
Company Summary
Based in Carlsbad, CA, Ionis Pharmaceuticals discovers/develops RNA-targeted therapeutics using its proprietary antisense oligonucleotide technology. The company leverages this technology to generate a broad pipeline of medicines, targeting neurological, cardiovascular and specialty rare diseases, for itself as well as its partners.
Ionis has phase III studies ongoing for nine medicines (internal as well as partnered) across 11 indications. These include tofersen for amyotrophic lateral sclerosis (ALS) with superoxide dismutase 1 (SOD1) mutations; pelacarsen for cardiovascular disease due to elevated Lp(a) levels; olezarsen for familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG); eplontersen for TTR amyloidosis; ulefnersen (ION363) for ALS, with mutations in the fused in sarcoma gene (FUS); donidalorsen for hereditary angioedema (HAE); bepirovirsen for chronic hepatitis B virus (CHB); IONIS-FB-LRx for immunoglobulin A nephropathy (IgAN) and geographic atrophy (GA); and zilganersen in Alexander’s disease.
Ionis has licensed Spinraza to Biogen, which is responsible for commercializing the drug approved for treating spinal muscular atrophy (SMA) worldwide. Ionis receives royalties from Biogen on Spinraza’s sales.
In the first half of 2021, Ionis completed the transition of the commercial operations for its other two commercialized products, Tegsedi (hereditary TTR amyloidosis, or hATTR amyloidosis) and Waylivra (genetically confirmed FCS), in Europe and North America to Swedish Orphan Biovitrum AB, or Sobi, per a distribution agreement with the company. With these deals, its European and North American operations for Tegsedi and Waylivra were restructured from direct sales to a distribution model.
Ionis earns commercial revenues primarily in the form of royalty payments on net sales of Spinraza. In 2023, Ionis generated $787.6 million in revenues, up 34% year over year. Total revenues included $308.6 million in commercial revenues and $479 million in research and development (R&D) revenues (upfront payments, milestone payments and license fees from partnered medicines).
General Information
Ionis Pharmaceuticals, Inc
2855 GAZELLE COURT
CARLSBAD, CA 92010
Phone: 760-931-9200
Fax: 760-603-2700
Web: http://www.ionispharma.com
Email: info@ionisph.com
Industry | Medical - Drugs |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 3/31/2024 |
Earnings Date | 5/7/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -1.01 |
Current Year EPS Consensus Estimate | -3.69 |
Estimated Long-Term EPS Growth Rate | NA |
Earnings Date | 5/7/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 41.84 |
52 Week High | 54.44 |
52 Week Low | 34.32 |
Beta | 0.39 |
20 Day Moving Average | 856,031.81 |
Target Price Consensus | 60.47 |
4 Week | -4.06 |
12 Week | -16.40 |
YTD | -17.79 |
4 Week | -1.16 |
12 Week | -18.72 |
YTD | -21.86 |
Shares Outstanding (millions) | 145.75 |
Market Capitalization (millions) | 6,061.74 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | 83.78% |
vs. Previous Quarter | 94.17% |
vs. Previous Year | 113.82% |
vs. Previous Quarter | 125.69% |
Price/Book | 15.43 |
Price/Cash Flow | NA |
Price / Sales | 7.69 |
3/31/24 | NA |
12/31/23 | -90.29 |
9/30/23 | -90.50 |
3/31/24 | NA |
12/31/23 | -12.39 |
9/30/23 | -14.41 |
3/31/24 | NA |
12/31/23 | 5.90 |
9/30/23 | 6.39 |
3/31/24 | NA |
12/31/23 | 5.83 |
9/30/23 | 6.33 |
3/31/24 | NA |
12/31/23 | -46.32 |
9/30/23 | -66.34 |
3/31/24 | NA |
12/31/23 | -46.32 |
9/30/23 | -66.34 |
3/31/24 | NA |
12/31/23 | -42.40 |
9/30/23 | -61.06 |
3/31/24 | NA |
12/31/23 | 2.70 |
9/30/23 | 2.20 |
3/31/24 | NA |
12/31/23 | 0.36 |
9/30/23 | 0.41 |
3/31/24 | NA |
12/31/23 | 3.18 |
9/30/23 | 4.06 |
3/31/24 | NA |
12/31/23 | 76.07 |
9/30/23 | 80.22 |